ArticleRoyal Society open science2020
Nano-MOFs as targeted drug delivery agents to combat antibiotic-resistant bacterial infections.
Article in Royal Society open science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 52 citations in OpenAlex.
- Tannic Acid and Copper-Modified ZIF-8 Metal Organic Framework as a Cefotaxime Delivery System for Antimicrobial ActivityTurkish journal of pharmaceutical sciences · 2026Article
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- Synthesis and Characterisation of Multivariate Metal-Organic Frameworks for Controlled Doxorubicin Absorption and Release.Molecules (Basel, Switzerland) · 2025Article
- Antibacterial and wound healing effects of PEG-coated ciprofloxacin-loaded ZIF-8 nanozymes against ciprofloxacin-resistantFrontiers in pharmacology · 2025Article
- PMA-Zeolite: Chemistry and Diverse Medical Applications.Journal of functional biomaterials · 2024Review
- Recent Progress in Multifunctional Stimuli-Responsive Combinational Drug Delivery Systems for the Treatment of Biofilm-Forming Bacterial Infections.Pharmaceutics · 2024Review
- Article
- Advances in Nanomaterials and Composites Based on Mesoporous Materials as Antimicrobial Agents: Relevant Applications in Human Health.Antibiotics (Basel, Switzerland) · 2024Review
- Advancements in nanoparticle-based treatment approaches for skin cancer therapy.Molecular cancer · 2023Review
- Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.Molecular cancer · 2023Review
- Dual Sensitization via Electron and Energy Harvesting in a Nanohybrid for Improvement of Therapeutic Efficacy.ACS physical chemistry Au · 2022Article
- Functionalized Erythrocyte Membrane-Coated Nanoparticles for the Treatment ofFrontiers in microbiology · 2022Article
- Metal-Organic Frameworks and Their Composites Towards Biomedical Applications.Frontiers in molecular biosciences · 2021Review
- Nano-MOFs as targeted drug delivery agents to combat antibiotic-resistant bacterial infections.Royal Society open science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug resistance of bacteria is a significant threat to human civilization while the action of antibiotics against drug-resistant bacteria is severely limited owing to the hydrophobic nature of drug molecules, which unquestionably inhibit its permanency for clinical applications. The antibacterial action of nanomaterials offers major modalities to combat drug resistance of bacteria. The current work reports the use of nano-metal-organic frameworks encapsulating drug molecules to enhance its antibacterial activity against model drug-resistant bacteria and biofilm of the bacteria. We have attached rifampicin (RF), a well-documented antituberculosis drug with tremendous pharmacological significance, into the pore surface of zeolitic imidazolate framework 8 (ZIF8) by a simple synthetic procedure. The synthesized ZIF8 has been characterized using the X-ray diffraction (XRD) method before and after drug encapsulation. The electron microscopic strategies such as scanning electron microscope and transmission electron microscope methods were performed to characterize the binding between ZIF8 and RF. We have also performed picosecond-resolved fluorescence spectroscopy to validate the formation of the ZIF8-RF nanohybrids (NHs). The drug release profile experiment demonstrates that ZIF8-RF depicts pH-responsive drug delivery and is ideal for targeting bacterial disease corresponding to its inherent acidic nature. Most remarkably, ZIF8-RF gives enhanced antibacterial activity against methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.